Collection, Processing and Infusion of Adult Hematopoietic Stem Cells (Bone Marrow and Peripheral Blood Stem Cells)

2008 ◽  
pp. 309-317
Author(s):  
Leslie Andritsos ◽  
Candace Paprocki ◽  
Andrew Yeager
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Hematopoietic Stem Cells ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cells ◽  
Hematopoietic Stem ◽  
Blood Stem Cells

Haplo-Identical Allogeneic Stem Cell Transplantation Using GCSF-Mobilized Marrow Plus Blood Stem Cells from Parent Donors for Children with High-Risk Leukemia.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 5084-5084
Author(s):  
Quanyi Lu ◽  
Xiaoqing Niu ◽  
Peng Zhang ◽  
Delong Liu
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Stem Cell ◽  
High Risk ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cells ◽  
Hematopoietic Stem ◽  
Blood Stem Cells

Abstract Increasing number of patients in China have difficulty of finding sibling donors due to limited number of siblings. We therefore explored the feasibility using haploidentical parent donors for allogeneic hematopoietic stem cell transplantation. Eight leukemia patients were studied in our hospital. These included 2 CML-BC, 2 MDS-RAEB, 3 relapsed ALL and 1 relapsed AML. The median age was 12 (7–17). GCSF- mobilized bone marrow and peripheral blood stem cells were collected from parents (1 to 3 locus mismatched). The conditioning regimen consisted of fludarabine (30mg/m2/d x5), bulsulfan (4mg/kg/d x3) and cyclophosphamide (50mg/kg/d x2). Cyclosporin A, mycophenolate mofetil, methotrexate, and ATG were used for GVHD prophylaxis. The total number of CD34+ cell in the grafts ranged between 5–10 x 106/kg. The median follow- up was 13 months (6–24). One patient failed to engraft, the other 7 patients achieved full donor chimerism at day 28. The incidence of acute GVHD (grade II-IV) was 57.1% (4 of 7). The incidence of chronic GVHD of limited stage occurred in the same 4 patients. One patient died of lung complication at 17th month, another patient with CML-BC relapsed 10 months after transplantation. The rest 6 patients are alive without disease. These results suggested that parents could be considered as stem cell donors in the absence of alternative donors for young patients with high-risk diseases. GCSF-primed bone marrow plus peripheral blood stem cells might be beneficial to reduce the risk of GVHD for leukemia children in China. More patients are needed to further study this approach.

Allogeneic Hematopoietic Stem Cell Donation—Current Status with Regard to Safety

2011 ◽  
Vol 07 (02) ◽  
pp. 153
Author(s):  
Alberto Bosi ◽  
Benedetta Bartolozzi ◽  
◽  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Stem Cell ◽  
Hematopoietic Stem Cell ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cells ◽  
Hematopoietic Stem ◽  
First Choice ◽  
Donation Process ◽  
Blood Stem Cells

Allogeneic hematopoietic stem cell transplantation (HSCT) represents the first choice of treatment or an important therapeutic option for numerous diseases. Several stem cell sources, such as bone marrow, mobilized peripheral blood stem cells, and umbilical cord blood, are suitable for HSCT in clinical practice. However, this procedure is strongly related to availability of a histocompatible donor. In order to increase the probability of finding a histocompatible donor, national and international registries have been developed. Voluntary donation of bone marrow or peripheral blood stem cells for HSCT, both in the related or unrelated setting, is a well-established procedure with an invaluable ethical significance. Even if both procedures are safe, they are not risk free; therefore, the greatest attention has to be paid to the donor and to the donation process through a careful monitoring protocol for donor safety.

scholarly journals Peripheral blood stem cells: mobilization strategies and potential therapeutic applications

2017 ◽  
Vol 4 (4) ◽  
pp. 876
Author(s):  
Hemlata Chhabra ◽  
Jaianand Kannaiyan ◽  
Palaniyandi M. ◽  
Rajangam B. ◽  
Suriya N. S. ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Peripheral Blood ◽  
Hematologic Malignancies ◽  
Peripheral Blood Stem Cells ◽  
Hematopoietic Stem ◽  
Cd34 Antigen ◽  
Blood Stem Cells ◽  
Bone Marrow Harvesting

Peripheral blood stem cell (PBSC) transplantation is now a day’s preferred transplantation source of stem cells as treatment modality for various hematologic malignancies. Progenitor hematopoietic stem cells express CD34 antigen, through which PBSCs are selected and collected. Peripheral blood stem cells provide a rapid and effective hematopoietic recovery after administration in patients having hematological ailments, with the advantages of a shorter engraftment time and the lack of a need for surgical procedure necessary for bone marrow harvesting. PBSCs are routinely present in blood circulation; though number too low to be used for transplantation. PBSCs can be mobilized by the administration of G-CSF or GM-CSF alone or preceded by chemotherapy. The yield of stem cells after mobilization differ enormously with disease condition, age etc. and several studies have been performed with different mobilizing regimen and factors affecting yield of progenitor cells. Mobilized peripheral blood stem cells have been increasingly used clinically for many diseases including myeloma, leukemia, lymphoma etc. In the current review, we give brief introduction about peripheral blood stem cells, its advantages over bone marrow and emphasize on different mobilizing strategy used for mobilizing PBSCs and expansion of these PBSCs under in vitro environment. The potential clinical application of PBSCs in treating different diseases has also been reviewed here in detail.

Cytokine-Mediated Expansion of 5-FU Resistant Peripheral Blood Stem Cells and Bone Marrow: Self-Renewal and Commitment Capacity*

1994 ◽  
Vol 3 (2) ◽  
pp. 135-139
Author(s):  
ALISON RICE ◽  
JEAN-MICHEL BOIRON ◽  
CAROLINE BARBOT ◽  
MARYSE DUPOUY ◽  
NADINE DUBSOC-MARCHENAY ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cells ◽  
Self Renewal ◽  
Blood Stem Cells

scholarly journals Timing of Peripheral Blood Stem Cell Yield: Comparison of Alternative Methods with the Classic Method for CD34+Cell Determination

2014 ◽  
Vol 2014 ◽  
pp. 1-13 ◽  
Author(s):  
I. Fatorova ◽  
M. Blaha ◽  
M. Lanska ◽  
D. Vokurkova ◽  
V. Rezacova ◽  
...  
Keyword(s):  
Stem Cells ◽  
Peripheral Blood ◽  
Reference Method ◽  
Roc Curves ◽  
Alternative Methods ◽  
Optimal Timing ◽  
Hematopoietic Tissue ◽  
Peripheral Blood Stem Cells ◽  
Hematopoietic Stem ◽  
Blood Stem Cells

Hematopoietic stem cells (HSCs), still represent a certain mystery in biology, have a unique property of dividing into equal cells and repopulating the hematopoietic tissue. This potential enables their use in transplantation treatments. The quality of the HSC grafts for transplantation is evaluated by flow cytometric determination of the CD34+cells, which enables optimal timing of the first apheresis and the acquisition of maximal yield of the peripheral blood stem cells (PBSCs). To identify a more efficient method for evaluating CD34+cells, we compared the following alternative methods with the reference method: hematopoietic progenitor cells (HPC) enumeration (using the Sysmex XE-2100 analyser), detection of CD133+cells, and quantification of aldehyde dehydrogenase activity in the PBSCs. 266 aphereses (84 patients) were evaluated. In the preapheretic blood, the new methods produced data that were in agreement with the reference method. The ROC curves have shown that for the first-day apheresis target, the optimal predictive cut-off value was 0.032 cells/mL for the HPC method (sensitivity 73.4%, specificity 69.3%). HPC method exhibited a definite practical superiority as compared to other methods tested. HPC enumeration could serve as a supplementary method for the optimal timing of the first apheresis; it is simple, rapid, and cheap.

Sign in / Sign up

Export Citation Format

Share Document